Rate Control in Atrial Fibrillation

Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02251509

Enrollment

Registered

2014-09-29

Start date

2016-12-31

Completion date

2017-09-30

Last updated

2016-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

This study will evaluate the efficacy of metoprolol tartrate compared to carvedilol on heart rate control in patients with atrial fibrillation and a rapid ventricular rate.

Interventions

DRUGCarvedilol

DRUGMetoprolol tartrate

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Permanent atrial fibrillation * Baseline ventricular rate (prior to treatment) \> 110 bpm

Exclusion criteria

* History of accessory tract re-entry tachycardia * Ejection fraction \< 35% or history of NYHA Class III/IV stage C/D heart failure * Acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery in the past 2 months * Child-Pugh class B or C hepatic dysfunction * Uncontrolled hypertension * Thyroid disease * Intolerance to beta-blockers * History of lung disease resulting in hospitalization in the past year

Design outcomes

Primary

Measure	Time frame	Description
Resting heart rate	2 weeks	Resting heart rate less than 80 bpm

Countries

United States

Contacts

Primary ContactCaroline Nubel

carolinenubel@creighton.edu(402) 280-4032

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026